May 11, 2023 / 03:15PM GMT
Jason Matthew Gerberry - BofA Securities, Research Division - MD in US Equity Research
We're going to get going here with our next company presenter at the BofA Annual Healthcare Conference. My name is Jason Gerberry. I'm one of the biotech analysts, and I'm pleased to be introducing our next company presenter, bluebird bio. We've got with us Andrew Obenshain, CEO; and Tom Klima, Chief Commercial Officer. So gentlemen, first off, thanks for joining us.
Andrew Obenshain - bluebird bio, Inc. - President, CEO & Director
Thank you. Thanks for having us.
Questions and Answers:
Jason Matthew Gerberry - BofA Securities, Research Division - MD in US Equity ResearchSo bluebird is a company in effectively developing functional cures, gene therapies for complex and rare diseases. And you're now kind of at a point where you're pivoting from an R&D stage company to a commercial stage company, you've got 2 approved gene therapies, one on the way filed for -- what do you think, your biggest market opportunity in
Trustpilot
